Table 2.
Clinical features and medications received in adult myositis patients with and without AMA
| AMA positive % (n/N) or Mean (SD) | AMA negative % (n/N) or Mean (SD) | Univariate p-value | Multivariate p-value | Total | |
|---|---|---|---|---|---|
| (N=32) | (N=587) | (N=619) | |||
| Heart involvement | |||||
| Heart involvementa | 16% (5/32) | 8% (49/587) | 0.2 | 0.2 | 9% (54/619) |
| Cardiomyopathy | 16% (5/32) | 5% (26/587) | 0.02 | 0.01 | 5% (31/619) |
| (N=30) | (N=450) | (N=480) | |||
| Muscle weakness | |||||
| At disease onset | 43% (13/30) | 42% (191/450) | 0.9 | 0.9 | 42% (204/480) |
| At follow up visits | 90% (27/30) | 62% (280/450) | 0.002 | 0.005 | 64% (307/480) |
| Skin involvement | |||||
| DM-specific skin involvementb | 60% (18/30) | 41% (186/450) | 0.05 | 0.04 | 42% (204/480) |
| Raynaud's phenomenon | 43% (13/30) | 14% (64/450) | < 0.001 | < 0.001 | 16% (77/480) |
| Mechanics hands | 20% (6/30) | 20% (92/450) | 1.0 | 1.0 | 20% (98/480) |
| Calcinosis | 10% (3/30) | 9% (42/450) | 0.8 | 0.8 | 9% (45/480) |
| Subcutaneous edema | 7% (2/30) | 13% (60/450) | 0.4 | 0.3 | 13% (62/480) |
| Lung involvement | |||||
| Interstitial lung disease | 20% (6/30) | 20% (91/450) | 1.0 | 1.0 | 20% (97/480) |
| Esophageal involvement | |||||
| Gastroesophageal reflux disease | 27% (8/30) | 19% (86/450) | 0.3 | 0.3 | 20% (94/480) |
| Dysphagia | 63% (19/30) | 36% (160/450) | 0.002 | 0.003 | 37% (179/480) |
| Joint involvement | |||||
| Arthritis | 20% (6/30) | 18% (80/450) | 0.8 | 0.7 | 18% (86/480) |
| Arthralgia | 47% (14/30) | 34% (151/450) | 0.1 | 0.1 | 34% (165/480) |
| Systemic involvement | |||||
| Fever | 10% (3/30) | 11% (50/450) | 1.0 | 0.9 | 11% (53/480) |
| Cancer associated myositis | 17% (5/30) | 11% (49/450) | 0.4 | 0.2 | 12% (54/480) |
| Treatments Received | |||||
| Corticosteroids | 90% (27/30) | 67% (301/450) | 0.008 | 0.04 | 68% (328/480) |
| Azathioprine | 30% (9/30) | 24% (110/450) | 0.5 | 0.6 | 25% (119/480) |
| Methotrexate | 40% (12/30) | 39% (176/450) | 0.9 | 0.8 | 39% (188/480) |
| Mycophenolate | 33% (10/30) | 22% (99/450) | 0.2 | 0.3 | 23% (109/480) |
| IVIG | 60% (18/30) | 29% (132/450) | < 0.001 | 0.003 | 31% (150/480) |
| Rituximab | 27% (8/30) | 14% (63/450) | 0.07 | 0.08 | 15% (71/480) |
| Total number of medications c | 2.8 (1.4) | 2.0 (1.5) | 0.003 | 0.002 | 2.0 (1.5) |
Dichotomous variables were expressed as percentage (count) and continuous variables as mean (SD). Univariate comparisons of continuous variables were made using Student’s t-test while dichotomous variables were compared either using chi-squared test or Fisher’s exact test, as appropriate. Multivariate comparisons were performed using linear regression for continuous variables and logistic regression for dichotomous variables. All multivariate comparisons were adjusted by gender and clinical group (inclusion body myositis or autoantibody group).
Abbreviations: IVIG: intravenous immunoglobulin
Myocarditis, atrial tachycardia, heart block, and/or cardiomyopathy.
Gottron’s papules and/or heliotrope rash
Total number of medications received at follow up, including corticosteroids, mycophenolate, methotrexate, IVIG, azathioprine, rituximab and cyclophosphamide